Immortagen logo

Two University of Iowa spinout ventures received $25,000 each in grants from the State of Iowa. These Proof of Commercial Relevance grants (POCR) will be used for confirming earlier marketing analyzes, product positioning, and pricing models. Immortagen is entering the personalized cancer treatment market for women's cancers. NatureMIRI will soon begin marketing microRNAs for the research market.